Bromonordiazepam:Exports & Compliance White Paper 2026

I. Executive Summary

7-Bromo-5-phenyl-1,2-dihydro-2H-1,4-benzodiazepin-2-one (CAS 2894-61-3) carries the 1,4-benzodiazepine heterocyclic core bearing phenyl substitution at the 5-position and bromine at the 7-position. It is handled commercially as a pharmaceutical intermediate and research-grade substance, and it is supplied exclusively business-to-business to verified legal entities. The material is not a medicine, has no approved therapeutic indication of its own, is not a dietary supplement, and is not offered for human or veterinary administration in any form. Every legitimate transaction begins with the buyer's credentials rather than with a quotation, and every serious supplier in this category maintains a screening function that reviews those credentials before any order is accepted.

The reason is structural policy rather than marketing preference. Substantial numbers of 1,4-benzodiazepine derivatives are under international control, several listed in Schedule IV of the United Nations Convention on Psychotropic Substances of 1971, while individual states parties implement those obligations through national statutes whose scope differs considerably. Some jurisdictions schedule by chemical name, others by family description, and a growing number apply generic or analogue definitions. The consequence for trade is that the control status of this particular intermediate must be established destination by destination, shipment by shipment, through documented verification rather than assumption.

This white paper therefore addresses only the compliant channel: custom synthesis and process development for qualified customers under valid permits, analytical characterisation, end-use declaration and know-your-customer screening, import and export licensing, the interaction between drug-control law and chemical law such as REACH, CLP and TSCA, and waste disposal with anti-diversion auditing. No operating detail is provided, since such detail would serve no legitimate purpose.

II. Product Deep Dive: Molecular Mechanisms and Production Evolution

2.1 Physicochemical Properties and Mechanisms

The following description is deliberately confined to structural and documentary characteristics. It contains no reagent quantities, conditions or yields, and is written so that procurement and compliance personnel can assess handling requirements without receiving diversion-enabling information.

• Identity and structural features: the compound corresponds to C15H11BrN2O, with a nominal mass near 315 Da, combining a seven-membered diazepine ring fused to an aromatic nucleus, a pendant phenyl group and a single bromine atom that shifts molecular weight, lipophilicity and mass-spectrometric behaviour in predictable ways. It is typically handled as a solid of limited aqueous solubility with better solubility in polar aprotic media, and is generally stored protected from light and moisture under conditions the supplier defines from its own stability data.
• Position within the heterocyclic family: as a member of the 1,4-benzodiazepin-2-one family it is chemically adjacent to a group of internationally surveyed structures, which is why its commercial handling is shaped less by unit economics than by licensing. Legitimate demand originates from registered research programmes exploring family chemistry and from laboratories that require characterised material as an analytical comparator, impurity standard or metabolite marker in support of authorised work.

2.2 Synthesis and Manufacturing Technologies

Production of this class is undertaken by manufacturing organisations that hold the permits required at their own location and that can demonstrate chain-of-custody and batch reconciliation controls to auditors and competent authorities. Accordingly the following remarks describe recognised route families in generic terms only, at the level customary in regulatory filings and supplier audits, and omit all operating parameters.

• Skeleton construction: industrial and laboratory routes to the 1,4-benzodiazepin-2-one core generally fall into two families: annulation of appropriately substituted aminobenzophenone-type starting materials with a bifunctional amino component to close the seven-membered ring, and later-stage elaboration of a preformed heterocycle. Route selection is discussed between licensed partners in terms of impurity profile, robustness and regulatory acceptability, and the chosen route is documented in the relevant dossier or technical agreement rather than in public commercial material.
• Halogen introduction, purification and verification: the bromine substituent may be introduced either before ring construction or on the assembled heterocycle by conventional electrophilic aromatic substitution, with the principal technical challenge being regioisomeric control and management of halogenated by-products. Final purification is typically achieved by crystallisation, preparative chromatography or both, and identity and purity are confirmed by orthogonal methods such as liquid chromatography with mass spectrometry and nuclear magnetic resonance spectroscopy.

2.3 Core Application Matrix

• Registered pharmaceutical process research: supplied as a building block or late-stage intermediate to licensed pharmaceutical and contract manufacturing partners for legitimate route development, impurity identification and scale-up studies, always under an executed quality agreement and after verification of the recipient's authorisations.
• Analytical and forensic reference material: produced as a characterised reference substance for toxicology, forensic and quality-control laboratories that already hold whatever licences their national authorities impose for acquiring family members, and distributed with documentation restricted to the licensed recipient.
• Impurity and metabolite standards for authorised dossiers: used in support of licensed registration work to identify and quantify related substances, degradation products and metabolic markers, which requires well-characterised material, complete certificates of analysis and traceable batch records.

III. Global Market Supply-Demand Landscape and Export Trends

3.1 Demand Drivers and Market Shifts

Demand in this category is modest in tonnage and unusual in its determinants. Volumes are measured in grams to low kilograms per programme, and demand follows three lawful drivers: expanding licensed heterocyclic research, widening official analytical reference collections, and continued transfer of early process development to partners. Because qualified purchasers are few, availability of a compliant supply route, rather than reactor capacity, is what constrains the market.

3.2 Capacity Distribution and Export Flows

Supply resides with a limited set of licensed manufacturers and specialised distributors rather than with open commodity producers. Chinese production, where permitted, is concentrated in established fine chemical parks serving export customers under verified destination authorisations; Indian supply is strongly oriented toward overseas innovator and contract research customers, supported by mature documentation practices; European and North American participants typically focus on reference-standard manufacture and high-compliance intermediate supply. Export flows therefore mirror regulatory relationships: consignments move along pre-approved corridors between known parties, and new corridors require weeks of verification before the first shipment.

3.3 Market Bifurcation and Pricing Dynamics

There is effectively no spot market. Quoted prices reflect the cost of compliance rather than synthesis alone: licensing, screening, secure storage, batch reconciliation, insurance, specialist packaging and audit overhead dominate the cost base, and analytical characterisation can exceed the cost of production by a wide margin. Payment terms are conservative, cancelled orders are rarely resaleable because records must balance, and quotations are conditional on a completed end-use declaration. Organisations evaluating offers should therefore treat unexplained price advantage as a compliance warning rather than as a bargain.

IV. In-depth Analysis of Global Compliance and Regulatory Barriers

Three legal layers apply simultaneously and independently. Drug-control law governs who may hold the material and for what purpose; ordinary chemical law governs registration, classification and labelling; and transport and waste law govern movement and disposal. Satisfying any one layer does not discharge the others, and most enforcement action arises from assuming otherwise.

4.1 European Market: REACH, CLP, and Sector-Specific Directives

• REACH, CLP and drug-precursor assessment: registration obligations attach once tonnage thresholds are exceeded, and classification and labelling notification to the harmonised inventory applies irrespective of volume, with the hazard classification assigned from the holder's own data. Additionally, materials of this structural class should be assessed against European and national drug-precursor control regimes before shipment, including Regulations 273/2004 and 111/2005 and national implementing lists, since obligations differ by member state.
• National licensing and end-use documentation: member states vary in how far associative or generic controls reach, and several require import or export authorisations for family members irrespective of the material's precise listing. Responsible exporters therefore obtain a destination-specific determination in writing, collect a signed end-use declaration naming the receiving institution and project, and retain records for the statutory period so that the file can be produced during inspection.

4.2 North American Market: TSCA, EPA, and FDA Regulations

• TSCA and research-development status: the substance must be positioned correctly on the inventory, and material supplied exclusively for evaluation may fall within the research and development exemption rather than an inventory listing, provided the conditions of that exemption, including supervision by technically qualified individuals and notification to recipients, are documented and respected.
• Controlled-substance interface and labelling: where a destination treats the structure as controlled, the recipient must hold the applicable registration and import authorisation before despatch, and the exporter must verify that authorisation against official records. Independently of that determination, the material carries no approval for therapeutic use: it must be documented and labelled for research or intermediate use only, never presented as a medicine, supplement or consumer article.

4.3 The Critical Hurdle: Quality Control and Safety Limits

V. Green Trade Barriers and ESG in Manufacturing

Environmental performance matters less here for carbon than for demonstrable control of halogenated waste and solvent streams, and it is assessed through the same audits that address security and quality.

5.1 Carbon Footprint and Circular Economy

Given gram-to-kilogram output, energy use is small in absolute terms but high per kilogram delivered, since most consumption arises from chromatographic purification, solvent distillation and cryogenic or refrigerated storage. Credible programmes report process mass intensity, recovered-solvent fractions and Scope 1 and 2 emissions from the producing site, and prefer route designs that reduce halogenated solvent use. Spent adsorbents, chromatographic media and mother liquors are routed to authorised hazardous waste incineration with documented destruction rather than to discharge, and certificates of destruction are retained alongside batch records.

5.2 Sustainable Sourcing and Traceability

Traceability in this category means batch-level accountability from synthesis through destruction. Facilities typically operate restricted access zones, dual-authority release, batch-number reconciliation from input to final container, documented destruction of intermediates and side streams, and periodic self-inspection covering deviation handling and employee screening alongside ISO 9001 and ISO 14001 certification. Buyers should audit precisely these controls, because a supplier unable to reconcile material movements cannot demonstrate that its production stayed inside the licensed channel, whatever its analytical certificates assert.

VI. Supply Chain Resilience and Export Logistics

Paperwork precedes packaging here, and predictability of the documentation set matters more than speed of carriage.

6.1 Packaging Standards and Moisture/Contamination Control

• Tamper-evident primary containment: material is sealed in chemically compatible primary containers with tamper-evident closures and unique container identification linked to the batch number, then placed in secondary containment with cushioning and, where appropriate, desiccant and light protection. The outer pack carries the minimum information required for carriage, the address of a named institutional recipient and no indication inviting consumer interest.
• Documentation set and custody records: each despatch travels with the certificate of analysis, the safety data sheet carrying the holder's own classification, a copy or reference to the applicable authorisation, and the recorded end-use declaration. Chain-of-custody records identify every person transferring or receiving the consignment, and intermediaries may not repackage, re-label or reconsign without written authorisation from the licence holder.

6.2 Dangerous Goods Identification and Transit Protocols

Physical transport hazards are typically modest, and most consignments are not assigned a dangerous-goods class; classification nevertheless depends on the supplier's data, and where hazardous-property classifications attach, the corresponding UN entry and packaging group must be applied. Customs detention, not physical risk, is the realistic source of delay, since officers routinely check authorisations against consignee identity. Air freight with signature-required delivery to institutional premises is standard, certain carriers decline the category altogether, and returns must be pre-authorised because re-importing controlled-adjacent material without documentation is itself an offence in many jurisdictions.

VII. Enterprise Global Expansion Strategy Guide

Growth in this category is earned through compliance maturity rather than through price or capacity investment, and the three priorities below reflect how competent operators actually expand.

1. Screen before quoting: establish a documented know-your-customer workflow that verifies legal entity registration, licence numbers against official registers, institutional affiliation, delivery address, and consistency between stated end use and requested quantity and specification, then check current destination-country control status. Only then issue a quotation, and only against a completed end-use declaration.
2. Build an auditable security and quality system: combine ISO 9001 certification for quality management with restricted access storage, batch reconciliation, dual-authority release, witnessed destruction of side streams and periodic self-audits. Suppliers of reference materials strengthen their position with accredited testing and reference-material production credentials.
3. Refuse the informal channel absolutely: sell only to verified institutions, decline anonymous or consumer-framed enquiries, maintain no retail or consumer-facing channel, avoid any presentation suggesting personal benefit or use, keep a register of suspicious-order assessments, and notify competent authorities where the applicable rules require it.

VIII. Conclusion

The commercial future of 7-Bromo-5-phenyl-1,2-dihydro-2H-1,4-benzodiazepin-2-one is decided by governance rather than by chemistry. Volumes will remain small, the customer base will remain narrow and institutional, and advantage will accrue to organisations able to prove that every gram was made, shipped and destroyed within an authorised trail of evidence.

Buyers and suppliers both benefit from planning around that reality: build lead time for permitting, choose partners whose records reconcile, insist on destination-specific determinations and resist any shortcut that removes verification from the process. Executed properly, the compliant channel delivers reliable access to a genuinely useful intermediate for legitimate research; executed carelessly, it exposes both parties to licence revocation, seizure and personal liability.

IX. Industry Resource Connection and Supplier Ecosystem

Powered by Guidechem

This white paper is exclusively compiled by the Guidechem Intelligence Team based on global customs data, regulatory databases, and industry research. Guidechem is a leading global B2B chemical platform, dedicated to connecting global buyers with verified, high-quality manufacturers.

Guidechem Global 7-Bromo-5-phenyl-1,2-dihydro-2H-1,4-benzodiazepin-2-one Supplier Ecosystem List

Relying on Guidechem's extensive global database, we have mapped the core participants in the current global 7-Bromo-5-phenyl-1,2-dihydro-2H-1,4-benzodiazepin-2-one supply chain:

• China, licensed fine chemical parks: permitted producers operate within established industrial parks serving export customers, combining heterocyclic synthesis capability with the analytical infrastructure needed for characterisation. Supply is released only after the destination authorisation has been verified, and the strongest participants maintain dedicated compliance teams that screen buyers, retain end-use declarations and reconcile batches from input to destruction.
• India, Hyderabad and Bengaluru research corridor: contractors oriented toward overseas innovator and contract research customers, offering custom synthesis, route scouting and analytical development supported by English-language documentation and familiarity with international permitting. Participants here tend to integrate supply within broader discovery programmes rather than shipping catalogued material.
• Europe and North America, reference-material specialists: smaller organisations focused on characterised reference substances and high-compliance intermediate supply, typically operating accredited testing laboratories and accredited reference-material production, with mature lawful-obligation screening. They serve forensic, toxicology and licensed industrial customers, and generally lead on documentation depth, traceability and engagement with competent authorities.